HIV-infected patients who switched from tenofovir disoproxil fumarate to tenofovir alafenamide had improvements in bone mineral density and kidney function.
The FDA recently approved a fixed-dose combination of elvitegravir/cobicistat/FTC/tenofovir alafenamide (E/C/FTC/TAF) for initial treatment of HIV-infected adults and adolescents (NEJM JW Infect Dis Dec 2015). Based on the results of a trial examining the safety and efficacy of switching to E/C/FTC/TAF from tenofovir disoproxil fumarate (TDF)-containing regimens, the FDA also approved this combination as a replacement for other regimens in patients who have been virologically suppressed for ≥6 months. Now, that industry-sponsored switch trial has been published.
A total of 1443 HIV-infected patients who had been virologically suppressed on one of four TDF-containing regimens (TDF and FTC — plus elvitegravir/cobicistat, ritonavir- or cobicist…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)